论文部分内容阅读
[Objective] To investigate the proliferation inhibition and apoptosis in human hepatic cancer cell strain HepG2 induced by ilexgenin A (3α, 19β, 20β-trihydroxyurs-12-ene-24, 28-dioic acid) and its mechanism. [Method] HepG2 were treated by ilexgenin A with different concentration (20, 40, 60, 80 mg/ml) and time (24, 36, 48 h). Methylthiazolyl tetrazolium bromide (MTT assay), acridine orange (AO) fluorescence staining method, SP method of immunocytechemistry and flow cytometry (FCM) were used to determine the inhibiting effects on HepG2 cells, the cell cycle and apoptosis morphological changes and the expressions of bcl-2, Bax. [Result] Ilexgenin A inhibited the proliferation of HepG2 cells in dosage and time dependent manner. The HepG2 cells that were treated by ilexgenin A for 24 h. Ilexgenin A induced a G1 cell cycle arrest and reduced the cell population in S phase. The apoptosis rate of cells treated by 40, 60 and 80 mg/ml ilexgenin A were 7.89%, 8.37%, 9.93% respectively. With the increasing of the medicine density, the expression of bcl-2 was down-regulated, while the expression of Bax up-regulated in the apoptosis. [Conclusion] Ilexgenin A can inhibit the proliferation of HepG2 ceils and induced a G1 cell cycle arrest and reduced the cell population in S phase. It also can induce apoptosis of human prostatic carcinoma through down-regulating the expressions of bcl-2 and up-regulating the expression of Bax.
[Objective] To investigate the proliferation inhibition and apoptosis in human hepatic cancer cell strain HepG2 induced by ilexgenin A (3α, 19β, 20β-trihydroxyurs-12-ene-24, 28-dioic acid) and its mechanism. [Method] treated by ilexgenin A with different concentrations (20, 40, 60, 80 mg / ml) and time (24, 36, 48 h). Methylthiazolyl tetrazolium bromide (MTT assay) immunocychemistry and flow cytometry (FCM) were used to determine the inhibiting effects on HepG2 cells, the cell cycle and apoptosis morphological changes and the expressions of bcl-2, Bax. [Result] Ilexgenin A inhibited the proliferation of HepG2 cells in dosage and time dependent manner. The HepG2 cells that were treated by ilexgenin A for 24 h. Ilexgenin A induced a G1 cell cycle arrest and reduced the cell population in S phase. The apoptosis rate of cells treated by 40, 60 and 80 mg / ml ilexgenin A were 7.89%, 8.37%, 9.93% respectively. With t he increasing of the medicine density, the expression of bcl-2 was down-regulated, while the expression of Bax up-regulated in the apoptosis. [Conclusion] Ilexgenin A can inhibit the proliferation of HepG2 ceils and induced a G1 cell cycle arrest and reduced the cell population in S phase. It also can induce apoptosis of human prostatic carcinoma through down-regulating the expressions of bcl-2 and up-regulating the expression of Bax.